Global Regenerative Medicine Market to Reach $50.55 Billion by 2025

Wednesday, January 24, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 23, 2018 /PRNewswire/ --

Global Regenerative Medicine Market to Reach $50.55 Billion by 2025

Due to the fall of the fertility rates, and increased life expectancy, the world population is ageing rapidly. The prevalence of diseases such as diabetes, osteoarthritis, cardiovascular diseases, Alzheimer's, and many others, are higher among
the elderly. As per the Arthritis Foundation, the older population in the U.S. affected by arthritis is estimated to grow to 21% by 2040, from the current value of 15%. Read the full report: The rising prevalence of chronic diseases is another factor contributing to the growth of the market. In the recent years, the prevalence of chronic diseases has been increasing irrespective of the age. As per WHO, the global prevalence of diabetes increased to 8.5% in adults over the age of 18 years in 2014 from 4.7% in 1980. The prevalence of genetic diseases, and cancer has also witnessed a rise in the recent years. Regenerative medicine presents with opportunities to change the treatment options, and offers complete cure of the diseases. The pharmaceutical industry is witnessing the growth of pipeline of candidates for regenerative medicine. A number of companies are now indulging in the research and development of such therapies. The regenerative medicine market includes various cellular, and acellular products. The market involves various therapies such as gene therapy, cell therapy, and tissue engineering. This therapy is being applied to a number of diseases, and therapeutic areas such as orthopaedic, cardiovascular, wound healing, diabetes, neurodegenerative, immune-oncology, and others. The market analysis includes an in-depth examination of the key ecosystem players, and the key strategies and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges), and industry analysis. The purpose of the study is to gain a holistic view of the regenerative medicine market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the regenerative medicine market. The market has been segmented into 'product', 'therapy', 'application', and 'geographical regions'. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market, and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into the consideration before entering the market. This research report aims at answering various aspects of the global regenerative medicine market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global regenerative medicine market, and assesses the factors governing the same. The answers to the following key questions can be derived from this report: • What are the major market drivers, challenges, and opportunities in the global regenerative medicine market? • How did the regenerative medicine market evolve, and what is its scope in the future? • What is the market share of the leading segments, and sub-segments of the global regenerative medicine market in 2017 and 2025? • How will each segment of the global regenerative medicine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025? • What are the influencing factors that may affect the market share of the key players? • How will the industry evolve during the forecast period 2017-2025? • What are the key developmental strategies implemented by the key players to stand out in this market? • What will be the growth rate of the tissue engineering segment during the forecast period? • Which therapy segment is expected to register the highest CAGR for the regenerative medicine market? • How has the market been segmented on the basis of application? Which application segment has the largest share, and growth rate in the regenerative medicine market? • What will be the value of immune-oncology segment by 2025? • Which geographical location will contribute to the highest sales of regenerative medicine? The key players that have been contributing significantly to the regenerative medicine market are Novartis AG, ViaCyte, Inc., Vericel Corporation, Tissue Regenix, Osiris Therapeutics, Inc., NuVasive, Inc., MiMedx Group Inc., Mesoblast Limited, Acelity, and Cytori Therapeutics, among others. Executive Summary The increased prevalence of chronic and genetic diseases has led to the high demand for better medicines. The existing therapies mostly treat the symptoms of the disease. But there was an impending need to identify the root-causes of any disease and then treat it accordingly. This need was effectively met with the advent of regenerative medicines in the medical world. Regenerative medicine is defined as the therapy involving the replacement or repair of the damaged tissue or organs, thereby completely curing the disease. The discovery of stem cells, the development of laboratory culture techniques, and the characterisation of pluripotent, and different stem cell types have together led to the development of regenerative medicine. Regenerative medicine represents a new paradigm in human health, with the potential to resolve unmet medical needs by addressing the underlying causes of disease. Regenerative medicine research translates fundamental knowledge in biology, chemistry and physics into materials, devices, systems and a variety of therapeutic strategies which augment, repair, replace or regenerate organs and tissues. This rapidly evolving, interdisciplinary field in healthcare is transforming the practice of medicine, medical innovation and the production of medical devices and therapies. The regenerative medicines market generated $17.03 billion revenue in 2016. The North America regenerative medicines market currently holds 39% percent of the global regenerative medicines market. Technological innovations across the various segments of the regenerative medicine have propelled growth in the recent past in the region. The global regenerative medicines market is expected to reach $50.55 billion by 2025. The rapid expansion of the stem cell and gene therapy in the developed markets such as the U.S., Japan, Germany, and the U.K. is key driver for growth of regenerative medicines market. As the world population is aging at a much faster pace, and the prevalence of diseases is rising, the demand is increasing for regenerative medicines that not only cure the chronic conditions completely but also improve the quality of life of the patients. Other factors contributing to the growth of the regenerative medicine market include the rising awareness about regenerative medicine, technological advancements, and better efficacy, and safety provided by such products. The major challenge to the growth of the market constitutes the changing regulatory environment. The stringent regulations implemented by the concerned regulatory bodies for the regenerative medicine products is a challenging factor for the industry players. The regenerative medicines market, cumulative of tissue engineering products, gene therapy, and stem cell therapy is fragmented in nature due to the involvement of numerous global as well as regional players (700+) in this industry. Most of the companies in this sector are in clinical stage and are expected to launch their products in the coming few years. The global regenerative medicines market is generally dominated by the global orthopedic and wound biologics companies, however, depending on the geographical areas the market of these players varies accordingly. Efficient distribution networks, product differentiation and supply competency play a major role in determining the market position of such players. Majority of these players are focusing on expanding distribution network as well as expanding presence, as Asia Pacific, Latin America and the Middle East are the developing regions and there is an increasing awareness about tissue and cell based products. The global regenerative medicine market on the basis of therapy can be segmented into cell therapy, gene therapy, and tissue engineering. The major contributor towards the market in 2016 was tissue engineering market with an estimated value of $10.78 billion in 2016. Based on the application type, the market is segmented into orthopaedic, cardiovascular, wound healing, diabetes, immune-oncology, and others. Moreover, based on the product type, the market can be segmented into cellular, and acellular products. Geographically, the largest contributor to the growth of the global regenerative medicine market was North America, attributing to the presence of various biopharmaceutical companies involved in R&D of regenerative products in the region followed by Europe. The highest CAGR was observed for Asia-pacific region due to encouraging regulatory decisions for regenerative medicine such as in Japan. Regenerative medicine cures the disease at the root cause, thus offering permanent treatment, unlike the palliative treatment offered by pharmaceutical products. The possibility of the development of a therapy for the treatment of rare, and orphan diseases, use of nanomaterials, and the recent development of cell free therapy, stem cell exosomes, present opportunities for the further growth of the global regenerative medicine market. The report provides in-depth SWOT analysis of different key players of the market, supported by an extensive financial summary of each. Some of the key players are Novartis AG, ViaCyte, Inc., Vericel Corporation, Tissue Regenix, Osiris Therapeutics, Inc., NuVasive, Inc., MiMedx Group Inc., Mesoblast Limited, Acelity, and Cytori Therapeutics. Countries Covered • North America • Europe • Asia Pacific • Rest of the WorldRead the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001


Cision View original content:

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store